Add time:07/17/2019         Source:sciencedirect.com

3D ligand-based virtual screening was employed to identify novel scaffolds for cannabinoid receptor ligand development. A total of 112 compounds with diverse structures were purchased from commercial vendors. 12 CB1 receptor antagonists/inverse agonists and 10 CB2 receptor agonists were identified in vitro. One of the CB2 agonists, N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine (19, −log EC50 = 7.5, Emax = 255%) was selected for further development. As far as we are aware, the compound’s 1,3,5-triazine scaffold represents a new core structure for CB2 agonists. A library of fifty-seven 2,4,6-trisubstituted-1,3,5-triazines was created to clarify the structure–activity relationship study of the analogs.

We also recommend Trading Suppliers and Manufacturers of 1,3,5-triazine-2,4,6(1H,3H,5H)-trione, compound with 1,3,5-triazine-2,4,6-triamine (cas 16133-31-6). Pls Click Website Link as below: cas 16133-31-6 suppliers